A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Summary

The purpose of this study is to evaluate the percentage of participants with a response of very good partial response (VGPR) or better to IDd treatment.

Timeline

Start

2018-03-13

Primary completion

2022-01-01

Completion

2023-06-26

Publications

• Delimpasi S, Dimopoulos MA, Straub J, Symeonidis A, Pour L, Hajek R, Touzeau C, Bhanderi VK, Berdeja JG, Pavlicek P, Matous JV, Robak PJ, Suryanarayan K, Miller A, Villarreal M, Cherepanov D, Srimani JK, Yao H, Labotka R, Orlowski RZ. Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma. Am J Hematol. 2024 Sep;99(9):1746-1756. doi: 10.1002/ajh.27382. Epub 2024 Jun 10.

Drugs

Indications